HeartSciences Files Its Fiscal 2026 Annual Report on Form 10-K

All hype, no numbers—wait for real financials before making any investment move.

What the company is saying

HeartSciences Inc. is positioning itself as a company at a pivotal moment, emphasizing the filing of its Annual Report and the imminent filing of a proxy statement for a proposed business combination with Fortitude Mining Holdings, Inc. The company’s narrative is that this transaction represents a 'significant opportunity' for shareholders, promising continued ownership in a business that is supposedly operating at scale, generating meaningful revenue, and backed by an established investor. The announcement highlights the launch of MyoVista Insights and claims fiscal 2026 as a 'landmark year,' suggesting a transition to mainstream commercial revenue, though no supporting data is provided. The language is aspirational and forward-looking, with repeated references to future disclosures—such as an upcoming earnings release and business update—rather than present achievements. Management’s tone is neutral but leans positive, using superlatives like 'landmark' and 'significant opportunity' to frame the narrative, while omitting any hard financial or operational metrics. The announcement also introduces Fortitude as an 'institutional-scale, vertically integrated venture mining platform' anchored in Zcash, again without quantification. Notable individuals named include Andrew Simpson, CEO of HeartSciences, and Mark Komonoski, Partner, but their specific roles in the transaction or operational execution are not detailed. The overall communication style is process-driven, focusing on regulatory steps and anticipated future events, fitting a strategy of keeping investors engaged with the promise of transformative change rather than substantiated results.

What the data suggests

The only concrete data disclosed is the filing of the Annual Report on Form 10-K for the fiscal year ended April 30, 2026, with the SEC on July 23, 2026. No financial results—such as revenue, net income, cash flow, or balance sheet figures—are provided in this announcement. There is no evidence of operational performance, profitability, or even basic sales metrics for either HeartSciences or Fortitude. The company claims fiscal 2026 was a 'landmark year' and references a transition to commercial revenue, but offers no numbers to support these assertions. There is also no disclosure of the proposed transaction’s value, terms, or expected financial impact. The gap between the company’s claims and the evidence is stark: all substantive statements about scale, revenue, or opportunity are unsupported by data. No prior targets or guidance are referenced, and there is no way to assess whether any internal or external expectations have been met. The quality of disclosure is poor—key metrics are missing, and the announcement is not transparent about the company’s financial health or the economics of the proposed merger. An independent analyst, relying solely on this announcement, would conclude that there is no basis for evaluating the company’s financial trajectory or the merits of the proposed transaction at this time.

Analysis

The announcement is framed with positive language, describing fiscal 2026 as a 'landmark year' and the proposed transaction as a 'significant opportunity,' but provides no measurable financial or operational data to support these claims. Nearly all substantive statements are forward-looking or aspirational, such as expectations to file proxy materials, anticipated earnings releases, and projected benefits of the merger. There is mention of large-scale, capital-intensive operations (venture mining platform, data centers, power contracts), but no disclosure of transaction value, committed funding, or immediate earnings impact. The only realised fact is the filing of the Form 10-K, which is a regulatory requirement and not an operational milestone. The gap between narrative and evidence is wide: the company inflates the signal with superlative language and projections, but offers no numbers or binding commitments. The lack of any profitability, revenue, or cash flow data means the announcement cannot be considered a positive investment signal.

Risk flags

• ●Lack of financial disclosure: The announcement provides no revenue, profit, cash flow, or balance sheet data for HeartSciences or Fortitude. This prevents investors from assessing the company’s financial health or the economics of the proposed transaction, increasing the risk of negative surprises when actual results are eventually disclosed.
• ●High forward-looking content: The majority of substantive statements are forward-looking, including the anticipated proxy filing, earnings release, and projected benefits of the merger. This means investors are being asked to buy into a narrative rather than evidence, which is a classic risk flag for overpromising and underdelivering.
• ●Capital intensity without detail: The announcement references 'institutional-scale' mining, data centers, and long-term power contracts, all of which are capital-intensive. However, there is no disclosure of how these will be funded, what the capital requirements are, or whether the company has secured the necessary resources. This raises the risk of future dilution, debt, or failed execution.
• ●Transaction uncertainty: The proposed business combination is not yet finalized and is subject to multiple approvals, including from shareholders and regulators. There is explicit acknowledgment that the transaction may not be completed on the anticipated timeline or at all, which introduces significant deal risk.
• ●Sector and operational mismatch: HeartSciences is a healthcare technology company, while Fortitude operates in digital asset mining. The lack of explanation for how these businesses will be integrated or create synergies increases the risk of operational misalignment and failed post-merger execution.
• ●Opaque claims of scale and revenue: The company asserts that Fortitude is operating at scale and generating meaningful revenue, but provides no numbers or third-party validation. This lack of transparency makes it impossible to verify the claims and increases the risk of overstatement.
• ●Reliance on future disclosures: The announcement repeatedly defers substantive information to future filings and updates. This pattern of promising more detail later, without providing any now, is a red flag for investors seeking actionable information.
• ●Exposure to volatile sectors: Fortitude’s operations are anchored in Zcash and the Proof-of-Work ecosystem, both of which are subject to extreme price volatility, regulatory uncertainty, and rapid technological change. This adds a layer of risk that is not quantified or mitigated in the announcement.

Bottom line

For investors, this announcement is almost entirely process and narrative, with no actionable financial or operational data. The only realized fact is the filing of a regulatory document—a basic compliance step, not a business achievement. All substantive claims about growth, revenue, scale, or opportunity are unsupported by numbers, making the narrative more hype than substance. The involvement of named individuals like Andrew Simpson (CEO) and Mark Komonoski (Partner) is noted, but without detail on their roles in the transaction or operational execution, their presence does not materially change the risk profile or credibility of the announcement. To change this assessment, the company would need to disclose concrete financial results for fiscal 2026, detailed transaction terms, and binding commitments related to the merger. Investors should watch for the upcoming earnings release and proxy statement, but should treat this announcement as a placeholder rather than a signal to act. The lack of transparency and reliance on future promises means this update is not actionable for investment purposes at this time. The single most important takeaway is that until HeartSciences provides real numbers and binding agreements, investors should remain on the sidelines and demand substance over story.

Announcement summary

(NASDAQ:HSCS) HeartSciences Inc. announced that it has filed its Annual Report on Form 10-K for the fiscal year ended April 30, 2026 with the U.S. Securities and Exchange Commission. The Company also expects to file shortly with the SEC a preliminary proxy statement in connection with its recently announced proposed business combination and related transactions with Fortitude Mining Holdings, Inc., currently wholly-owned by Digital Currency Group. Fiscal 2026 was described as a landmark year for HeartSciences, with the launch of MyoVista Insights and the beginning of its transition to mainstream commercial revenue. The Company stated that the proxy statement will set out the transaction in detail and that it intends to issue its fiscal 2026 earnings release and a business update, currently expected early next week. Fortitude is described as an institutional-scale, vertically integrated venture mining platform operating across the Proof-of-Work ecosystem and anchored in Zcash. The press release contains forward-looking statements concerning HeartSciences, Fortitude and the Proposed Transaction and other matters. HeartSciences and Fortitude, their respective directors and executive officers, and certain executive officers of DCG may be deemed to be participants in the solicitation of proxies from HeartSciences’ shareholders with respect to the Proposed Transaction.

Disagree with this article?